1. Home
  2. YRD vs NGNE Comparison

YRD vs NGNE Comparison

Compare YRD & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yiren Digital Ltd.

YRD

Yiren Digital Ltd.

HOLD

Current Price

$4.51

Market Cap

407.8M

Sector

Finance

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.28

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YRD
NGNE
Founded
2012
2003
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
407.8M
327.8M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
YRD
NGNE
Price
$4.51
$20.28
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$38.50
AVG Volume (30 Days)
75.8K
239.9K
Earning Date
11-25-2025
11-13-2025
Dividend Yield
9.76%
N/A
EPS Growth
N/A
N/A
EPS
2.03
N/A
Revenue
$872,820,262.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.23
N/A
Revenue Growth
10.41
N/A
52 Week Low
$4.15
$6.88
52 Week High
$8.74
$37.27

Technical Indicators

Market Signals
Indicator
YRD
NGNE
Relative Strength Index (RSI) 36.66 39.47
Support Level $4.27 $19.23
Resistance Level $4.64 $23.00
Average True Range (ATR) 0.21 1.60
MACD 0.02 -0.09
Stochastic Oscillator 37.14 26.57

Price Performance

Historical Comparison
YRD
NGNE

About YRD Yiren Digital Ltd.

Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: